agm thursday nov3, page-40

Yes, good post meg, and thanks for reminding us of Martin's reply to my questions.

As for wisdom - by your own admission a rant, and I won't respond to such irrelevant and widesweeping comparisons.

Back on-topic: meg, my concerns about lack of Phase III data and the rollout in some markets were addressed and well answered by Martin. You should note in my post on this thread the following points which are not in conflict with my earlier response to Martin's email:

1 - I state that safety data is available that provides support but that it is on small numbers.
2 - my concerns about the rollout without Phase III data is a "niggle" in my mind about the company. I do not condemn completely this move, but it is of concern.
3 - I reiterated my reassurance in the quality of the personnel at Prima as being reassuring in the context of the Dubai rollout. And in fact had given a link to such information earlier in the thread.

While it may suit your argument to characterise my post today as possibly inconsistent with the earlier one, in fact it is not. Martin's reply was very reassuring at the time, and still is, although not completely reassuring in purely scientific terms (i.e. when referenced to FDA standards)

Rhyspoo: cheap shot saying my thinking is driven by financial interest. It is not. But ad hominem attacks such as that I have become immune to on this forum.